Image de couverture de The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

De : Doctor V.Dyachkov
Écouter gratuitement

La meilleure offre de la saison | 0,99 €/mois pendant les 3 premiers mois + 15 € de crédit Audible

6,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
À propos de ce titre
Type 2 diabetes isn't just about medication — it's about understanding how your daily habits create a loop that shapes your blood sugar. Each episode breaks down clinical research from PubMed.gov randomized controlled trials, revealing how diet, exercise, sleep, and stress influence glucose. Learn how continuous monitoring transforms treatment, how apps like Blood Sugar • Diabetes Control https://play.google.com/store/apps/details?id=com.flycode.sugarlevel Disclaimer: This podcast is for informational and educational purposes only and does not replace professional medical helpDoctor V.Dyachkov Hygiene & gesundes Leben
épisodes
  • Cardiovascular Risk in Type 2 Diabetes: Why SGLT2 + GLP-1 Combo Is a Game-Changer
    19 Nov 2026

    SGLT2 GLP-1 combination therapy may be the biggest shift in cardiovascular risk type 2 diabetes care this decade. A 2025 systematic review of over 1.1 million participants found that combining SGLT2 inhibitors and GLP-1 receptor agonists may cut major adverse cardiovascular events by 44%. In this episode we unpack how these two drug classes work differently, why combination therapy T2D outperformed monotherapy, and what the numbers actually show: MACE risk reduction RR 0.56, kidney composite endpoint RR 0.48, all-cause mortality RR 0.50, and cardiovascular mortality RR 0.26. We also cover the pooled safety profile — no increased risk of severe hypoglycemia or DKA — and why randomized trials are still needed before this becomes routine clinical practice.

    Institutional AI Design • Agent-to-Agent Era

    Transcript: In this transcript we break down the SGLT2 GLP-1 combination, cardiovascular risk type 2 diabetes evidence, and combination therapy T2D outcomes from a review of over 1.1 million participants.

    Research Source – PubMed: SGLT2 + GLP-1 PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=SGLT2+GLP-1+combination+cardiovascular+type+2+diabetes)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    afficher plus Afficher moins
    51 min
  • CGM Without Insulin: 82% of Non-Insulin Type 2 Diabetes Patients Improved Hyperglycemia (ADA 2026)
    12 Nov 2026

    CGM without insulin is changing type 2 diabetes care. A 2026 study presented at the American Diabetes Association's annual meeting found that 82% of adults with Type 2 diabetes not on insulin substantially reduced hyperglycemia using CGM. This episode explores how CGM without insulin works, why non-insulin type 2 diabetes monitoring matters, and what this means for the newly diagnosed and those managing with oral medications. We cover over-the-counter CGM options for non-insulin users, barriers to access, and how to overcome them. If you thought CGM was only for insulin users, this episode will change everything.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • The study population: adults with T2D not using insulin.
    • How CGM reduced hyperglycemia without insulin therapy.
    • Implications for the newly diagnosed and those managing with oral medications.
    • Over-the-counter CGM options for non-insulin users.
    • Barriers to access and how to overcome them.
    • Why CGM without insulin is becoming a core question in type 2 diabetes monitoring.

    Key Studies Referenced

    • 2026 ADA annual meeting study: 82% of non-insulin-treated adults with T2D substantially reduced hyperglycemia using CGM.
    • Analysis of CGM use in non-insulin type 2 diabetes and implications for oral medication management.
    • Real-world barriers to CGM access for non-insulin users and emerging over-the-counter options.

    Resources & Links

    Research Source – PubMed: CGM Without Insulin PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=CGM+without+insulin+type+2+diabetes)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack CGM without insulin: why 82% of non-insulin type 2 diabetes patients improved hyperglycemia, and what that means for monitoring, oral medications, and access.”

    SEO Keywords: CGM without insulin, non-insulin type 2 diabetes monitoring, hyperglycemia reduction, type 2 diabetes CGM, over-the-counter CGM, ADA 2026, continuous glucose monitor, diabetes technology, oral medication diabetes, CGM access, Sugar Level app, diabetes support.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    afficher plus Afficher moins
    32 min
  • CGM vs Fingerstick: What the FreeDM2 Trial Really Means for Basal Insulin Users
    5 Nov 2026

    FreeDM2 trial: CGM vs fingerstick — a landmark 2026 randomized controlled trial across 24 UK centers just proved what many suspected: real-time CGM beats self-monitoring of blood glucose for people on basal insulin, and the gap only widens over time. In this episode, we break down the FreeDM2 trial design: 303 adults with type 2 diabetes on basal insulin plus SGLT2i or GLP-1 RA. HbA1c results at 16 weeks and 32 weeks show the CGM group dropping to 7.8% vs. 8.3% in the fingerstick arm. We explain why the benefit persisted during both self-management and clinician-supported phases, why severe hypoglycemia occurred twice in the SMBG control group and zero times in the CGM group, and what this means for insurance coverage, clinical practice, and real-time CGM type 2 diabetes care.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • FreeDM2 trial design: 303 adults, basal insulin plus SGLT2i or GLP-1 RA.
    • HbA1c results at 16 weeks and 32 weeks: CGM group drops to 7.8% vs. 8.3%.
    • Why the benefit persisted during both self-management and clinician-supported phases.
    • Severe hypoglycemia rates: two instances in the SMBG control group, none in CGM.
    • What this means for insurance coverage and clinical practice.
    • Why real-time CGM vs fingerstick is now a central question in type 2 diabetes care.

    Key Studies Referenced

    • FreeDM2 trial: 2026 randomized controlled trial across 24 UK centers.
    • 303 adults with type 2 diabetes on basal insulin plus SGLT2i or GLP-1 RA.
    • HbA1c at 16 and 32 weeks: real-time CGM vs self-monitoring of blood glucose.
    • Severe hypoglycemia: two events in the SMBG control group, zero in the CGM group.

    Resources & Links

    Research Source – PubMed: FreeDM2 Trial PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=FreeDM2+trial+CGM+fingerstick)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack the FreeDM2 trial: CGM vs fingerstick — and why real-time CGM type 2 diabetes management just got its strongest evidence yet.”

    SEO Keywords: FreeDM2 trial, CGM vs fingerstick, real-time CGM type 2 diabetes, basal insulin, SGLT2i, GLP-1 RA, HbA1c 7.8 vs 8.3, severe hypoglycemia, continuous glucose monitor, diabetes technology, CGM insurance coverage, type 2 diabetes clinical trial.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    afficher plus Afficher moins
    23 min
adbl_web_anon_alc_button_suppression_t1
Aucune critique pour le moment